Many effective drugs that are already developed will not reach patients for years because the clinical trial system is the primary bottleneck. This delay is due to logistical and structural inefficiencies in testing, not a lack of scientific discovery.

Many peptides are unlikely to ever receive FDA approval because their simple, easily replicated structures make them commodities. Pharma companies won't fund billion-dollar trials for drugs they can't patent, leaving them in a permanent gray market.

The Myriad Genetics case made naturally occurring compounds unpatentable. This removed the financial incentive for pharmaceutical companies to spend hundreds of millions on FDA trials for peptides, which are naturally derived. Compounding pharmacies filled the void until a 2023 FDA ban pushed these promising compounds into a risky, unregulated gray market.

Biotech companies are incentivized to own the entire intellectual property for a drug, from delivery to molecule. This leads to endless litigation and siloed innovation, preventing the combination of "best-in-class" components from different companies and ultimately slowing progress for patients.

Our ability to generate and test therapeutic hypotheses in silico is rapidly outpacing the slow, expensive conventional clinical trial system. Without regulatory reform, the pipeline of promising drugs will remain stuck, preventing breakthroughs from reaching patients. The science is solvable; the system is not.

A medically-proven hangover cure doesn't exist mainly because the economics are unviable. The high cost of clinical trials, potentially hundreds of millions of dollars, is prohibitive for a product that would likely be low-margin and based on non-patentable ingredients, offering no clear path to profitability.

The debate over Thymosin alpha-1 highlights a key market failure. Because it's an existing molecule that is difficult to patent, major pharmaceutical companies lack the financial incentive to fund expensive US FDA trials. This creates a vacuum where a potentially effective drug is only accessible through unregulated channels.

BPC-157's journey from a Croatian lab to bodybuilding forums, where users ordered it from Chinese factories, highlights a user-driven drug development model. This path, fueled by online communities and podcasts, completely circumvents the conventional, regulated pharmaceutical pipeline, presenting both opportunities for unmet needs and significant safety risks.

Pharmaceutical companies view the healthcare market as a battle for a patient's total spending capacity. They lobby against non-patentable compounds like peptides not because they have a direct competitor, but because every dollar spent on a compounded peptide is a dollar not spent on one of their high-margin, patented prescription drugs, thus protecting their overall revenue.